Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Peripher Nerv Syst ; 11(1): 77-87, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16519786

ABSTRACT

The protein zero (P0) glycoprotein is an important component of compact peripheral nerve myelin produced by the glial cells of the mammalian peripheral nervous system. P0 mRNA expression is reduced following exposure of Schwann cells to sublytic C5b-9, the terminal activation complex of the complement cascade. Sublytic complement treatment decreased P0 mRNA by 81% within 6 h and required C5b-9 assembly. C5b-9 induced a threefold increase in both JNK1 activity and c-jun mRNA within 20 and 30 min, respectively, compared with cells treated with either human serum depleted of complement component C7 (C7dHS) or medium alone. Sublytic C5b-9 stimulation, in the presence of the transcription inhibitor Actinomycin D, decreased P0 mRNA expression by 52%, indicating that mRNA was selectively destabilized. This effect was prevented by pretreatment with L-JNK inhibitor 1 (L-JNKI1). To study a potential inhibition of P0 gene transcription, we transfected Schwann cells with a P0 promoter-firefly luciferase construct. Sublytic C5b-9 stimulation of the transfected cells decreased luciferase activity by 82% at 6 h, and this effect was prevented by pretreatment with L-JNKI1 inhibitor. Our results indicate that the ability of C5b-9 in vitro to affect P0 gene expression is mediated via JNK1 activation that leads to enhanced mRNA decay and transcriptional repression of P0.


Subject(s)
Complement Membrane Attack Complex/metabolism , Enzyme Activation/physiology , Mitogen-Activated Protein Kinase 8/metabolism , Myelin P0 Protein/metabolism , Schwann Cells/metabolism , Animals , Blotting, Northern , Complement Membrane Attack Complex/drug effects , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Gene Expression/physiology , Mitogen-Activated Protein Kinase 8/drug effects , Myelin P0 Protein/drug effects , Myelin P0 Protein/genetics , RNA Stability/physiology , RNA, Messenger , Rats , Rats, Sprague-Dawley , Schwann Cells/drug effects , Transcription, Genetic
2.
Prog Neurobiol ; 71(1): 57-66, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14611868

ABSTRACT

The process of aging deeply influences morphological and functional parameters of peripheral nerves. The observations summarized here indicate that the deterioration of myelin occurring in the peripheral nerves during aging may be explained by the fall of the levels of the major peripheral myelin proteins [e.g., glycoprotein Po (Po) and peripheral myelin protein 22 (PMP22)]. Neuroactive steroids, such as progesterone (PROG), dihydroprogesterone (5alpha-DH PROG), and tetrahydroprogesterone (3alpha,5alpha-TH PROG), are able to stimulate the low expression of these two myelin proteins present in the sciatic nerve of aged male rats. Since Po and PMP22 play an important physiological role in the maintenance of the multilamellar structure of PNS myelin, we have evaluated the effect of PROG and its neuroactive derivatives, 5alpha-DH PROG and 3alpha,5alpha-TH PROG, on the morphological alterations of myelinated fibers in the sciatic nerve of 22-24-month-old male rats. Data obtained clearly indicate that neuroactive steroids are able to reduce aging-associated morphological abnormalities of myelin and aging-associated myelin fiber loss in the sciatic nerve.


Subject(s)
Aging , Myelin Sheath/drug effects , Peripheral Nervous System Diseases/drug therapy , Peripheral Nervous System Diseases/prevention & control , Progesterone/pharmacology , Aging/pathology , Aging/physiology , Animals , Male , Myelin P0 Protein/drug effects , Myelin P0 Protein/physiology , Myelin Proteins/drug effects , Myelin Proteins/physiology , Peripheral Nervous System Diseases/pathology , Progesterone/analogs & derivatives
3.
Exp Neurol ; 184(2): 930-8, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14769385

ABSTRACT

The observations here reported indicate that, in vivo, the expression of an important protein of peripheral myelin, the glycoprotein Po, is influenced by mifespristone (RU 38486), that is, an antagonist of progesterone (PR) and glucocorticoid (GR) receptor. In our experimental model, male rats have been treated at the first day of life with this antagonist and after repeated treatments, we have analyzed in the sciatic nerve of 20- (20d) and 30-day-old rats (30d) the mRNA and protein levels of Po. Moreover, expression of Po has also been analyzed in the sciatic nerve of animals treated during the first 30 days of postnatal life and then sacrificed at 90th day of life (90d). The results obtained have indicated that both mRNA and protein levels of Po decrease at 20d. Apparently, these effects seem to be transient because no changes are evident at the other two times of analysis. As shown by morphometric analysis, the treatment with RU 38486 is also able to induce morphological changes at the level of sciatic nerve. However, at variance to what is expected by an alteration of an important component of the myelin membranes like Po, no changes are evident at the level of the myelin compartment. On the contrary, a significant reduction of axon diameter in parallel to an increase in neurofilament (NF) density occurs since 30d. In conclusion, the present data seem to suggest that progestin and/or glucocorticoid signals are not only involved in the control of myelin compartment but also on the axon maintenance.


Subject(s)
Hormone Antagonists/pharmacology , Mifepristone/pharmacology , Myelin P0 Protein/biosynthesis , Myelin P0 Protein/drug effects , Sciatic Nerve/drug effects , Animals , Axons/drug effects , Axons/ultrastructure , Blotting, Northern , Blotting, Western , Male , Microscopy, Electron , Myelin P0 Protein/ultrastructure , Myelin Sheath/drug effects , Myelin Sheath/ultrastructure , Neurofilament Proteins/drug effects , Neurofilament Proteins/ultrastructure , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Sciatic Nerve/ultrastructure
4.
Dev Neurosci ; 24(2-3): 214-21, 2002.
Article in English | MEDLINE | ID: mdl-12401961

ABSTRACT

Schwann cells (SCs) in culture, without the presence of axons, become de-differentiated, reaching a condition similar to that of their precursor cells. The cytoplasmic accumulation of transferrin (Tf) in the myelinated peripheral nerve has been reported and data in the literature support a role for apoTf in myelination in the CNS. In the present report, we used SC cultures to evaluate the capacity of apoTf and holoTf to prevent cell de-differentiation promoted by fetal calf serum deprivation. SCs incubated in a serum-free medium showed a decrease in the expression of myelin basic protein (MBP) and P(0), markers of mature myelin-forming SCs, together with an increase in the levels of p75NTR and glial fibrillary acidic protein, markers of immature SCs. Treatment with holoTf prevented the decrease in expression of MBP and P(0) and the increase in p75NTR. ApoTf was unable to prevent these changes except when iron was added to the cultures. These results suggest a role for holoTf in the regulation of myelin formation by SCs.


Subject(s)
Cell Differentiation/drug effects , Schwann Cells/drug effects , Transferrin/pharmacology , Animals , Animals, Newborn , Blotting, Western , Cell Differentiation/physiology , Cell Survival/drug effects , Cells, Cultured , Culture Media , Glial Fibrillary Acidic Protein/drug effects , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry , Iron/pharmacology , Myelin Basic Protein/drug effects , Myelin Basic Protein/metabolism , Myelin P0 Protein/drug effects , Myelin P0 Protein/metabolism , Rats , Receptor, Nerve Growth Factor , Receptors, Nerve Growth Factor/drug effects , Receptors, Nerve Growth Factor/metabolism , Schwann Cells/cytology , Schwann Cells/metabolism , Transferrin/metabolism
5.
Glia ; 27(1): 39-52, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10401631

ABSTRACT

Caveolae are non-clathrin-coated invaginations of the plasma membrane, which are present in most cell types. An integral component of caveolae is the caveolin family of related proteins, which not only forms the structural framework of caveolae, but also likely subserves its functional roles, including regulation of signal transduction and cellular transport, in particular, cholesterol trafficking. Although caveolae have been identified ultrastructurally in the peripheral nervous system (PNS), caveolin expression has not previously been studied. To date, three caveolin genes have been reported. Here, we show for the first time that caveolin-1 is expressed by Schwann cells (SC) as well as several SC-derived cell lines. Caveolin-1 is enriched in the buoyant, detergent-insoluble membranes of rat sciatic nerve (SN) and SC, a hallmark of the caveolar compartment. Caveolin-1 exists as both soluble and insoluble forms in rat SN and SC, and localizes to SC cytoplasm and abaxonal myelin. SC caveolin-1 decreases after axotomy, when SC revert to a premyelinating phenotype. We speculate that caveolin-1 may regulate signal transduction and/or cholesterol transport in myelinating SC.


Subject(s)
Caveolins , Membrane Proteins/analysis , Schwann Cells/chemistry , Sciatic Nerve/chemistry , Animals , Axotomy/adverse effects , Caveolin 1 , Cells, Cultured , Colforsin/pharmacology , Humans , Membrane Proteins/drug effects , Myelin P0 Protein/drug effects , Neuroblastoma/chemistry , Rats , Rats, Sprague-Dawley , Schwann Cells/physiology , Sciatic Nerve/physiology , Tumor Cells, Cultured
6.
Glia ; 25(4): 358-69, 1999 Feb 15.
Article in English | MEDLINE | ID: mdl-10028918

ABSTRACT

Peripheral myelin protein 22 (PMP22) was initially described as a minor component of peripheral myelin. Mutations affecting the PMP22 gene cause demyelinating neuropathies, supporting a role for the protein in PNS myelination. Furthermore, PMP22 carries the L2/HNK-1 carbohydrate epitope suggesting an adhesion/recognition function. Despite advances in characterizing the PMP22 gene, the specific role(s) of the protein in myelin remains unknown. In this study we determined the temporal expression pattern of PMP22 in comparison to galactocerebroside (GalC) and myelin associated glycoprotein (MAG), early constituents of PNS myelin, and to protein zero (P0) and myelin basic protein (MBP), late components of myelin. In sciatic nerve lysates, PMP22 was detected at postnatal day 3, after MAG, but before MBP expression. The same results were obtained in cocultures of dorsal root ganglion neurons and Schwann cells (SCs). Low levels of PMP22 were found in early, anti-MAG and anti-GalC immunoreactive, myelinating cocultures. However, PMP22 could only be detected in the SC plasma membrane after basal lamina formation. In long-term myelinating cocultures PMP22 levels continued to increase and the protein was found in anti-P0 and anti-MBP immunoreactive myelin segments. Furthermore, PMP22, MBP, and P0 protein levels were greatly enhanced by progesterone treatment of the cocultures. The highest levels of PMP22 expression were associated with late stages of myelination; however the presence of the protein in nonmyelinating SCs and in SCs commencing myelination supports multiple roles for PMP22 in peripheral nerve biology.


Subject(s)
Galactosylceramides/biosynthesis , Myelin Proteins/biosynthesis , Myelin Sheath/physiology , Animals , Animals, Newborn , Cells, Cultured , Myelin Basic Protein/biosynthesis , Myelin Basic Protein/drug effects , Myelin P0 Protein/biosynthesis , Myelin P0 Protein/drug effects , Myelin Proteins/drug effects , Myelin-Associated Glycoprotein/biosynthesis , Myelin-Associated Glycoprotein/drug effects , Progesterone/pharmacology , Rats , Schwann Cells/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...